Report cover image

Global Inactivated Influenza Virus Vaccine Market Outlook and Growth Opportunities 2025

Publisher APO Research, Inc.
Published Aug 16, 2025
Length 205 Pages
SKU # APRC20359584

Description

Summary

According to APO Research, the global Inactivated Influenza Virus Vaccine market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.

The North American market for Inactivated Influenza Virus Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Asia-Pacific market for Inactivated Influenza Virus Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

In China, the Inactivated Influenza Virus Vaccine market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Europe market for Inactivated Influenza Virus Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Major global companies in the Inactivated Influenza Virus Vaccine market include CSL, Zhejiang Tian Yuan Biopharmaceutical Co., Ltd, Changchun Institute of Biological Products Co., Ltd, Shanghai Institute of Biological Products Co., Ltd, Johnson & Johnson, Mylan, Lanzhou Institute of Biological Products Co., Ltd, Jiangsu Kangrun Biotechnology Co., Ltd and Jiangsu Jindik Biotechnology Co., Ltd, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Inactivated Influenza Virus Vaccine, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Inactivated Influenza Virus Vaccine, also provides the sales of main regions and countries. Of the upcoming market potential for Inactivated Influenza Virus Vaccine, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Inactivated Influenza Virus Vaccine sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Inactivated Influenza Virus Vaccine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Inactivated Influenza Virus Vaccine sales, projected growth trends, production technology, application and end-user industry.

Inactivated Influenza Virus Vaccine Segment by Company

CSL
Zhejiang Tian Yuan Biopharmaceutical Co., Ltd
Changchun Institute of Biological Products Co., Ltd
Shanghai Institute of Biological Products Co., Ltd
Johnson & Johnson
Mylan
Lanzhou Institute of Biological Products Co., Ltd
Jiangsu Kangrun Biotechnology Co., Ltd
Jiangsu Jindik Biotechnology Co., Ltd
Pfizer
Hualan Bio Vaccines Co., Ltd
GSK
Dalian Yalifeng Biopharmaceutical Co., Ltd
Beijing Kexing Biological Products Co., Ltd
Emmi Chengxin Biopharmaceutical Co., Ltd
AstraZeneca
Sanofi Pasteur
Inactivated Influenza Virus Vaccine Segment by Type

Whole Virus Vaccine
Subunit Vaccine
Inactivated Influenza Virus Vaccine Segment by Application

Hospital
Clinic
Inactivated Influenza Virus Vaccine Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global Inactivated Influenza Virus Vaccine status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Inactivated Influenza Virus Vaccine market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Inactivated Influenza Virus Vaccine significant trends, drivers, influence factors in global and regions.
6. To analyze Inactivated Influenza Virus Vaccine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Inactivated Influenza Virus Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Inactivated Influenza Virus Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Inactivated Influenza Virus Vaccine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Inactivated Influenza Virus Vaccine market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Inactivated Influenza Virus Vaccine industry.
Chapter 3: Detailed analysis of Inactivated Influenza Virus Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Inactivated Influenza Virus Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Inactivated Influenza Virus Vaccine in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.

Table of Contents

205 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global Inactivated Influenza Virus Vaccine Sales Value (2020-2031)
1.2.2 Global Inactivated Influenza Virus Vaccine Sales Volume (2020-2031)
1.2.3 Global Inactivated Influenza Virus Vaccine Sales Average Price (2020-2031)
1.3 Assumptions and Limitations
1.4 Study Goals and Objectives
2 Inactivated Influenza Virus Vaccine Market Dynamics
2.1 Inactivated Influenza Virus Vaccine Industry Trends
2.2 Inactivated Influenza Virus Vaccine Industry Drivers
2.3 Inactivated Influenza Virus Vaccine Industry Opportunities and Challenges
2.4 Inactivated Influenza Virus Vaccine Industry Restraints
3 Inactivated Influenza Virus Vaccine Market by Company
3.1 Global Inactivated Influenza Virus Vaccine Company Revenue Ranking in 2024
3.2 Global Inactivated Influenza Virus Vaccine Revenue by Company (2020-2025)
3.3 Global Inactivated Influenza Virus Vaccine Sales Volume by Company (2020-2025)
3.4 Global Inactivated Influenza Virus Vaccine Average Price by Company (2020-2025)
3.5 Global Inactivated Influenza Virus Vaccine Company Ranking (2023-2025)
3.6 Global Inactivated Influenza Virus Vaccine Company Manufacturing Base and Headquarters
3.7 Global Inactivated Influenza Virus Vaccine Company Product Type and Application
3.8 Global Inactivated Influenza Virus Vaccine Company Establishment Date
3.9 Market Competitive Analysis
3.9.1 Global Inactivated Influenza Virus Vaccine Market Concentration Ratio (CR5 and HHI)
3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
3.9.3 2024 Inactivated Influenza Virus Vaccine Tier 1, Tier 2, and Tier 3 Companies
3.10 Mergers and Acquisitions Expansion
4 Inactivated Influenza Virus Vaccine Market by Type
4.1 Inactivated Influenza Virus Vaccine Type Introduction
4.1.1 Whole Virus Vaccine
4.1.2 Subunit Vaccine
4.2 Global Inactivated Influenza Virus Vaccine Sales Volume by Type
4.2.1 Global Inactivated Influenza Virus Vaccine Sales Volume by Type (2020 VS 2024 VS 2031)
4.2.2 Global Inactivated Influenza Virus Vaccine Sales Volume by Type (2020-2031)
4.2.3 Global Inactivated Influenza Virus Vaccine Sales Volume Share by Type (2020-2031)
4.3 Global Inactivated Influenza Virus Vaccine Sales Value by Type
4.3.1 Global Inactivated Influenza Virus Vaccine Sales Value by Type (2020 VS 2024 VS 2031)
4.3.2 Global Inactivated Influenza Virus Vaccine Sales Value by Type (2020-2031)
4.3.3 Global Inactivated Influenza Virus Vaccine Sales Value Share by Type (2020-2031)
5 Inactivated Influenza Virus Vaccine Market by Application
5.1 Inactivated Influenza Virus Vaccine Application Introduction
5.1.1 Hospital
5.1.2 Clinic
5.2 Global Inactivated Influenza Virus Vaccine Sales Volume by Application
5.2.1 Global Inactivated Influenza Virus Vaccine Sales Volume by Application (2020 VS 2024 VS 2031)
5.2.2 Global Inactivated Influenza Virus Vaccine Sales Volume by Application (2020-2031)
5.2.3 Global Inactivated Influenza Virus Vaccine Sales Volume Share by Application (2020-2031)
5.3 Global Inactivated Influenza Virus Vaccine Sales Value by Application
5.3.1 Global Inactivated Influenza Virus Vaccine Sales Value by Application (2020 VS 2024 VS 2031)
5.3.2 Global Inactivated Influenza Virus Vaccine Sales Value by Application (2020-2031)
5.3.3 Global Inactivated Influenza Virus Vaccine Sales Value Share by Application (2020-2031)
6 Inactivated Influenza Virus Vaccine Regional Sales and Value Analysis
6.1 Global Inactivated Influenza Virus Vaccine Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Inactivated Influenza Virus Vaccine Sales by Region (2020-2031)
6.2.1 Global Inactivated Influenza Virus Vaccine Sales by Region: 2020-2025
6.2.2 Global Inactivated Influenza Virus Vaccine Sales by Region (2026-2031)
6.3 Global Inactivated Influenza Virus Vaccine Sales Value by Region: 2020 VS 2024 VS 2031
6.4 Global Inactivated Influenza Virus Vaccine Sales Value by Region (2020-2031)
6.4.1 Global Inactivated Influenza Virus Vaccine Sales Value by Region: 2020-2025
6.4.2 Global Inactivated Influenza Virus Vaccine Sales Value by Region (2026-2031)
6.5 Global Inactivated Influenza Virus Vaccine Market Price Analysis by Region (2020-2025)
6.6 North America
6.6.1 North America Inactivated Influenza Virus Vaccine Sales Value (2020-2031)
6.6.2 North America Inactivated Influenza Virus Vaccine Sales Value Share by Country, 2024 VS 2031
6.7 Europe
6.7.1 Europe Inactivated Influenza Virus Vaccine Sales Value (2020-2031)
6.7.2 Europe Inactivated Influenza Virus Vaccine Sales Value Share by Country, 2024 VS 2031
6.8 Asia-Pacific
6.8.1 Asia-Pacific Inactivated Influenza Virus Vaccine Sales Value (2020-2031)
6.8.2 Asia-Pacific Inactivated Influenza Virus Vaccine Sales Value Share by Country, 2024 VS 2031
6.9 South America
6.9.1 South America Inactivated Influenza Virus Vaccine Sales Value (2020-2031)
6.9.2 South America Inactivated Influenza Virus Vaccine Sales Value Share by Country, 2024 VS 2031
6.10 Middle East & Africa
6.10.1 Middle East & Africa Inactivated Influenza Virus Vaccine Sales Value (2020-2031)
6.10.2 Middle East & Africa Inactivated Influenza Virus Vaccine Sales Value Share by Country, 2024 VS 2031
7 Inactivated Influenza Virus Vaccine Country-level Sales and Value Analysis
7.1 Global Inactivated Influenza Virus Vaccine Sales by Country: 2020 VS 2024 VS 2031
7.2 Global Inactivated Influenza Virus Vaccine Sales Value by Country: 2020 VS 2024 VS 2031
7.3 Global Inactivated Influenza Virus Vaccine Sales by Country (2020-2031)
7.3.1 Global Inactivated Influenza Virus Vaccine Sales by Country (2020-2025)
7.3.2 Global Inactivated Influenza Virus Vaccine Sales by Country (2026-2031)
7.4 Global Inactivated Influenza Virus Vaccine Sales Value by Country (2020-2031)
7.4.1 Global Inactivated Influenza Virus Vaccine Sales Value by Country (2020-2025)
7.4.2 Global Inactivated Influenza Virus Vaccine Sales Value by Country (2026-2031)
7.5 USA
7.5.1 USA Inactivated Influenza Virus Vaccine Sales Value Growth Rate (2020-2031)
7.5.2 USA Inactivated Influenza Virus Vaccine Sales Value Share by Type, 2024 VS 2031
7.5.3 USA Inactivated Influenza Virus Vaccine Sales Value Share by Application, 2024 VS 2031
7.6 Canada
7.6.1 Canada Inactivated Influenza Virus Vaccine Sales Value Growth Rate (2020-2031)
7.6.2 Canada Inactivated Influenza Virus Vaccine Sales Value Share by Type, 2024 VS 2031
7.6.3 Canada Inactivated Influenza Virus Vaccine Sales Value Share by Application, 2024 VS 2031
7.7 Mexico
7.6.1 Mexico Inactivated Influenza Virus Vaccine Sales Value Growth Rate (2020-2031)
7.6.2 Mexico Inactivated Influenza Virus Vaccine Sales Value Share by Type, 2024 VS 2031
7.6.3 Mexico Inactivated Influenza Virus Vaccine Sales Value Share by Application, 2024 VS 2031
7.8 Germany
7.8.1 Germany Inactivated Influenza Virus Vaccine Sales Value Growth Rate (2020-2031)
7.8.2 Germany Inactivated Influenza Virus Vaccine Sales Value Share by Type, 2024 VS 2031
7.8.3 Germany Inactivated Influenza Virus Vaccine Sales Value Share by Application, 2024 VS 2031
7.9 France
7.9.1 France Inactivated Influenza Virus Vaccine Sales Value Growth Rate (2020-2031)
7.9.2 France Inactivated Influenza Virus Vaccine Sales Value Share by Type, 2024 VS 2031
7.9.3 France Inactivated Influenza Virus Vaccine Sales Value Share by Application, 2024 VS 2031
7.10 U.K.
7.10.1 U.K. Inactivated Influenza Virus Vaccine Sales Value Growth Rate (2020-2031)
7.10.2 U.K. Inactivated Influenza Virus Vaccine Sales Value Share by Type, 2024 VS 2031
7.10.3 U.K. Inactivated Influenza Virus Vaccine Sales Value Share by Application, 2024 VS 2031
7.11 Italy
7.11.1 Italy Inactivated Influenza Virus Vaccine Sales Value Growth Rate (2020-2031)
7.11.2 Italy Inactivated Influenza Virus Vaccine Sales Value Share by Type, 2024 VS 2031
7.11.3 Italy Inactivated Influenza Virus Vaccine Sales Value Share by Application, 2024 VS 2031
7.12 Spain
7.12.1 Spain Inactivated Influenza Virus Vaccine Sales Value Growth Rate (2020-2031)
7.12.2 Spain Inactivated Influenza Virus Vaccine Sales Value Share by Type, 2024 VS 2031
7.12.3 Spain Inactivated Influenza Virus Vaccine Sales Value Share by Application, 2024 VS 2031
7.13 Russia
7.13.1 Russia Inactivated Influenza Virus Vaccine Sales Value Growth Rate (2020-2031)
7.13.2 Russia Inactivated Influenza Virus Vaccine Sales Value Share by Type, 2024 VS 2031
7.13.3 Russia Inactivated Influenza Virus Vaccine Sales Value Share by Application, 2024 VS 2031
7.14 Netherlands
7.14.1 Netherlands Inactivated Influenza Virus Vaccine Sales Value Growth Rate (2020-2031)
7.14.2 Netherlands Inactivated Influenza Virus Vaccine Sales Value Share by Type, 2024 VS 2031
7.14.3 Netherlands Inactivated Influenza Virus Vaccine Sales Value Share by Application, 2024 VS 2031
7.15 Nordic Countries
7.15.1 Nordic Countries Inactivated Influenza Virus Vaccine Sales Value Growth Rate (2020-2031)
7.15.2 Nordic Countries Inactivated Influenza Virus Vaccine Sales Value Share by Type, 2024 VS 2031
7.15.3 Nordic Countries Inactivated Influenza Virus Vaccine Sales Value Share by Application, 2024 VS 2031
7.16 China
7.16.1 China Inactivated Influenza Virus Vaccine Sales Value Growth Rate (2020-2031)
7.16.2 China Inactivated Influenza Virus Vaccine Sales Value Share by Type, 2024 VS 2031
7.16.3 China Inactivated Influenza Virus Vaccine Sales Value Share by Application, 2024 VS 2031
7.17 Japan
7.17.1 Japan Inactivated Influenza Virus Vaccine Sales Value Growth Rate (2020-2031)
7.17.2 Japan Inactivated Influenza Virus Vaccine Sales Value Share by Type, 2024 VS 2031
7.17.3 Japan Inactivated Influenza Virus Vaccine Sales Value Share by Application, 2024 VS 2031
7.18 South Korea
7.18.1 South Korea Inactivated Influenza Virus Vaccine Sales Value Growth Rate (2020-2031)
7.18.2 South Korea Inactivated Influenza Virus Vaccine Sales Value Share by Type, 2024 VS 2031
7.18.3 South Korea Inactivated Influenza Virus Vaccine Sales Value Share by Application, 2024 VS 2031
7.19 India
7.19.1 India Inactivated Influenza Virus Vaccine Sales Value Growth Rate (2020-2031)
7.19.2 India Inactivated Influenza Virus Vaccine Sales Value Share by Type, 2024 VS 2031
7.19.3 India Inactivated Influenza Virus Vaccine Sales Value Share by Application, 2024 VS 2031
7.20 Australia
7.20.1 Australia Inactivated Influenza Virus Vaccine Sales Value Growth Rate (2020-2031)
7.20.2 Australia Inactivated Influenza Virus Vaccine Sales Value Share by Type, 2024 VS 2031
7.20.3 Australia Inactivated Influenza Virus Vaccine Sales Value Share by Application, 2024 VS 2031
7.21 Southeast Asia
7.21.1 Southeast Asia Inactivated Influenza Virus Vaccine Sales Value Growth Rate (2020-2031)
7.21.2 Southeast Asia Inactivated Influenza Virus Vaccine Sales Value Share by Type, 2024 VS 2031
7.21.3 Southeast Asia Inactivated Influenza Virus Vaccine Sales Value Share by Application, 2024 VS 2031
7.22 Brazil
7.22.1 Brazil Inactivated Influenza Virus Vaccine Sales Value Growth Rate (2020-2031)
7.22.2 Brazil Inactivated Influenza Virus Vaccine Sales Value Share by Type, 2024 VS 2031
7.22.3 Brazil Inactivated Influenza Virus Vaccine Sales Value Share by Application, 2024 VS 2031
7.23 Argentina
7.23.1 Argentina Inactivated Influenza Virus Vaccine Sales Value Growth Rate (2020-2031)
7.23.2 Argentina Inactivated Influenza Virus Vaccine Sales Value Share by Type, 2024 VS 2031
7.23.3 Argentina Inactivated Influenza Virus Vaccine Sales Value Share by Application, 2024 VS 2031
7.24 Chile
7.24.1 Chile Inactivated Influenza Virus Vaccine Sales Value Growth Rate (2020-2031)
7.24.2 Chile Inactivated Influenza Virus Vaccine Sales Value Share by Type, 2024 VS 2031
7.24.3 Chile Inactivated Influenza Virus Vaccine Sales Value Share by Application, 2024 VS 2031
7.25 Colombia
7.25.1 Colombia Inactivated Influenza Virus Vaccine Sales Value Growth Rate (2020-2031)
7.25.2 Colombia Inactivated Influenza Virus Vaccine Sales Value Share by Type, 2024 VS 2031
7.25.3 Colombia Inactivated Influenza Virus Vaccine Sales Value Share by Application, 2024 VS 2031
7.26 Peru
7.26.1 Peru Inactivated Influenza Virus Vaccine Sales Value Growth Rate (2020-2031)
7.26.2 Peru Inactivated Influenza Virus Vaccine Sales Value Share by Type, 2024 VS 2031
7.26.3 Peru Inactivated Influenza Virus Vaccine Sales Value Share by Application, 2024 VS 2031
7.27 Saudi Arabia
7.27.1 Saudi Arabia Inactivated Influenza Virus Vaccine Sales Value Growth Rate (2020-2031)
7.27.2 Saudi Arabia Inactivated Influenza Virus Vaccine Sales Value Share by Type, 2024 VS 2031
7.27.3 Saudi Arabia Inactivated Influenza Virus Vaccine Sales Value Share by Application, 2024 VS 2031
7.28 Israel
7.28.1 Israel Inactivated Influenza Virus Vaccine Sales Value Growth Rate (2020-2031)
7.28.2 Israel Inactivated Influenza Virus Vaccine Sales Value Share by Type, 2024 VS 2031
7.28.3 Israel Inactivated Influenza Virus Vaccine Sales Value Share by Application, 2024 VS 2031
7.29 UAE
7.29.1 UAE Inactivated Influenza Virus Vaccine Sales Value Growth Rate (2020-2031)
7.29.2 UAE Inactivated Influenza Virus Vaccine Sales Value Share by Type, 2024 VS 2031
7.29.3 UAE Inactivated Influenza Virus Vaccine Sales Value Share by Application, 2024 VS 2031
7.30 Turkey
7.30.1 Turkey Inactivated Influenza Virus Vaccine Sales Value Growth Rate (2020-2031)
7.30.2 Turkey Inactivated Influenza Virus Vaccine Sales Value Share by Type, 2024 VS 2031
7.30.3 Turkey Inactivated Influenza Virus Vaccine Sales Value Share by Application, 2024 VS 2031
7.31 Iran
7.31.1 Iran Inactivated Influenza Virus Vaccine Sales Value Growth Rate (2020-2031)
7.31.2 Iran Inactivated Influenza Virus Vaccine Sales Value Share by Type, 2024 VS 2031
7.31.3 Iran Inactivated Influenza Virus Vaccine Sales Value Share by Application, 2024 VS 2031
7.32 Egypt
7.32.1 Egypt Inactivated Influenza Virus Vaccine Sales Value Growth Rate (2020-2031)
7.32.2 Egypt Inactivated Influenza Virus Vaccine Sales Value Share by Type, 2024 VS 2031
7.32.3 Egypt Inactivated Influenza Virus Vaccine Sales Value Share by Application, 2024 VS 2031
8 Company Profiles
8.1 CSL
8.1.1 CSL Comapny Information
8.1.2 CSL Business Overview
8.1.3 CSL Inactivated Influenza Virus Vaccine Sales, Value and Gross Margin (2020-2025)
8.1.4 CSL Inactivated Influenza Virus Vaccine Product Portfolio
8.1.5 CSL Recent Developments
8.2 Zhejiang Tian Yuan Biopharmaceutical Co., Ltd
8.2.1 Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Comapny Information
8.2.2 Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Business Overview
8.2.3 Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Sales, Value and Gross Margin (2020-2025)
8.2.4 Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio
8.2.5 Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Recent Developments
8.3 Changchun Institute of Biological Products Co., Ltd
8.3.1 Changchun Institute of Biological Products Co., Ltd Comapny Information
8.3.2 Changchun Institute of Biological Products Co., Ltd Business Overview
8.3.3 Changchun Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Sales, Value and Gross Margin (2020-2025)
8.3.4 Changchun Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio
8.3.5 Changchun Institute of Biological Products Co., Ltd Recent Developments
8.4 Shanghai Institute of Biological Products Co., Ltd
8.4.1 Shanghai Institute of Biological Products Co., Ltd Comapny Information
8.4.2 Shanghai Institute of Biological Products Co., Ltd Business Overview
8.4.3 Shanghai Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Sales, Value and Gross Margin (2020-2025)
8.4.4 Shanghai Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio
8.4.5 Shanghai Institute of Biological Products Co., Ltd Recent Developments
8.5 Johnson & Johnson
8.5.1 Johnson & Johnson Comapny Information
8.5.2 Johnson & Johnson Business Overview
8.5.3 Johnson & Johnson Inactivated Influenza Virus Vaccine Sales, Value and Gross Margin (2020-2025)
8.5.4 Johnson & Johnson Inactivated Influenza Virus Vaccine Product Portfolio
8.5.5 Johnson & Johnson Recent Developments
8.6 Mylan
8.6.1 Mylan Comapny Information
8.6.2 Mylan Business Overview
8.6.3 Mylan Inactivated Influenza Virus Vaccine Sales, Value and Gross Margin (2020-2025)
8.6.4 Mylan Inactivated Influenza Virus Vaccine Product Portfolio
8.6.5 Mylan Recent Developments
8.7 Lanzhou Institute of Biological Products Co., Ltd
8.7.1 Lanzhou Institute of Biological Products Co., Ltd Comapny Information
8.7.2 Lanzhou Institute of Biological Products Co., Ltd Business Overview
8.7.3 Lanzhou Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Sales, Value and Gross Margin (2020-2025)
8.7.4 Lanzhou Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio
8.7.5 Lanzhou Institute of Biological Products Co., Ltd Recent Developments
8.8 Jiangsu Kangrun Biotechnology Co., Ltd
8.8.1 Jiangsu Kangrun Biotechnology Co., Ltd Comapny Information
8.8.2 Jiangsu Kangrun Biotechnology Co., Ltd Business Overview
8.8.3 Jiangsu Kangrun Biotechnology Co., Ltd Inactivated Influenza Virus Vaccine Sales, Value and Gross Margin (2020-2025)
8.8.4 Jiangsu Kangrun Biotechnology Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio
8.8.5 Jiangsu Kangrun Biotechnology Co., Ltd Recent Developments
8.9 Jiangsu Jindik Biotechnology Co., Ltd
8.9.1 Jiangsu Jindik Biotechnology Co., Ltd Comapny Information
8.9.2 Jiangsu Jindik Biotechnology Co., Ltd Business Overview
8.9.3 Jiangsu Jindik Biotechnology Co., Ltd Inactivated Influenza Virus Vaccine Sales, Value and Gross Margin (2020-2025)
8.9.4 Jiangsu Jindik Biotechnology Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio
8.9.5 Jiangsu Jindik Biotechnology Co., Ltd Recent Developments
8.10 Pfizer
8.10.1 Pfizer Comapny Information
8.10.2 Pfizer Business Overview
8.10.3 Pfizer Inactivated Influenza Virus Vaccine Sales, Value and Gross Margin (2020-2025)
8.10.4 Pfizer Inactivated Influenza Virus Vaccine Product Portfolio
8.10.5 Pfizer Recent Developments
8.11 Hualan Bio Vaccines Co., Ltd
8.11.1 Hualan Bio Vaccines Co., Ltd Comapny Information
8.11.2 Hualan Bio Vaccines Co., Ltd Business Overview
8.11.3 Hualan Bio Vaccines Co., Ltd Inactivated Influenza Virus Vaccine Sales, Value and Gross Margin (2020-2025)
8.11.4 Hualan Bio Vaccines Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio
8.11.5 Hualan Bio Vaccines Co., Ltd Recent Developments
8.12 GSK
8.12.1 GSK Comapny Information
8.12.2 GSK Business Overview
8.12.3 GSK Inactivated Influenza Virus Vaccine Sales, Value and Gross Margin (2020-2025)
8.12.4 GSK Inactivated Influenza Virus Vaccine Product Portfolio
8.12.5 GSK Recent Developments
8.13 Dalian Yalifeng Biopharmaceutical Co., Ltd
8.13.1 Dalian Yalifeng Biopharmaceutical Co., Ltd Comapny Information
8.13.2 Dalian Yalifeng Biopharmaceutical Co., Ltd Business Overview
8.13.3 Dalian Yalifeng Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Sales, Value and Gross Margin (2020-2025)
8.13.4 Dalian Yalifeng Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio
8.13.5 Dalian Yalifeng Biopharmaceutical Co., Ltd Recent Developments
8.14 Beijing Kexing Biological Products Co., Ltd
8.14.1 Beijing Kexing Biological Products Co., Ltd Comapny Information
8.14.2 Beijing Kexing Biological Products Co., Ltd Business Overview
8.14.3 Beijing Kexing Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Sales, Value and Gross Margin (2020-2025)
8.14.4 Beijing Kexing Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio
8.14.5 Beijing Kexing Biological Products Co., Ltd Recent Developments
8.15 Emmi Chengxin Biopharmaceutical Co., Ltd
8.15.1 Emmi Chengxin Biopharmaceutical Co., Ltd Comapny Information
8.15.2 Emmi Chengxin Biopharmaceutical Co., Ltd Business Overview
8.15.3 Emmi Chengxin Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Sales, Value and Gross Margin (2020-2025)
8.15.4 Emmi Chengxin Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio
8.15.5 Emmi Chengxin Biopharmaceutical Co., Ltd Recent Developments
8.16 AstraZeneca
8.16.1 AstraZeneca Comapny Information
8.16.2 AstraZeneca Business Overview
8.16.3 AstraZeneca Inactivated Influenza Virus Vaccine Sales, Value and Gross Margin (2020-2025)
8.16.4 AstraZeneca Inactivated Influenza Virus Vaccine Product Portfolio
8.16.5 AstraZeneca Recent Developments
8.17 Sanofi Pasteur
8.17.1 Sanofi Pasteur Comapny Information
8.17.2 Sanofi Pasteur Business Overview
8.17.3 Sanofi Pasteur Inactivated Influenza Virus Vaccine Sales, Value and Gross Margin (2020-2025)
8.17.4 Sanofi Pasteur Inactivated Influenza Virus Vaccine Product Portfolio
8.17.5 Sanofi Pasteur Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Inactivated Influenza Virus Vaccine Value Chain Analysis
9.1.1 Inactivated Influenza Virus Vaccine Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Inactivated Influenza Virus Vaccine Sales Mode & Process
9.2 Inactivated Influenza Virus Vaccine Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Inactivated Influenza Virus Vaccine Distributors
9.2.3 Inactivated Influenza Virus Vaccine Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.